Combination of isocitrate dehydrogenase 1 ( IDH 1 isocitrate dehydrogenase 1 ( IDH IDH 1 ) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism

摘要

Essentials Risk stratification for venous thromboembolism (VTE) in patients with brain tumors is challenging. Patients with IDH1 wildtype and high podoplanin expression have a 6‐month VTE risk of 18.2%. Patients with IDH1 mutation and no podoplanin expression have a 6‐month VTE risk of 0%. IDH1 mutation and podoplanin overexpression in primary brain tumors appear to be exclusive. Summary Background Venous thromboembolism ( VTE ) is a frequent complication in primary brain tumor patients. Independent studies revealed that podoplanin expression in brain tumors is associated with increased VTE risk, whereas the isocitrate dehydrogenase 1 ( IDH 1) mutation is associated with very low VTE risk. Objectives To investigate the interrelation between intratumoral podoplanin expression and IDH 1 mutation, and their mutual impact on VTE development. Patients/Methods In a prospective cohort study, intratumoral IDH 1 R132H mutation and podoplanin were determined in brain tumor specimens (mainly glioma) by immunohistochemistry. The primary endpoint of the study was symptomatic VTE during a 2‐year follow‐up. Results All brain tumors that expressed podoplanin to a medium‐high extent showed also an IDH 1 wild‐type status. A score based on IDH 1 status and podoplanin expression levels allowed prediction of the risk of VTE . Patients with wild‐type IDH 1 brain tumors and high podoplanin expression had a significantly increased VTE risk compared with those with mutant IDH 1 tumors and no podoplanin expression (6‐month risk 18.2% vs. 0%). Conclusions IDH 1 mutation and podoplanin overexpression seem to be exclusive. Although brain tumor patients with IDH 1 mutation are at very low risk of VTE , the risk of VTE in patients with IDH 1 wild‐type tumors is strongly linked to podoplanin expression levels.